Solvonis Therapeutics CEO Anthony Tennyson discusses 1.3M GBP fundraising and pipeline development

Solvonis Therapeutics CEO Anthony Tennyson details how a recent 1.3 million GBP capital raise will support clinical pipeline milestones across severe alcohol use disorder and psychiatric indications. Funding enables the expansion of international trial sites for SVN-001 in Europe, complementing an ongoing Phase 3 trial in the UK NHS for alcohol use disorder. The company is also advancing SVN-002, a sublingual thin film formulation of esketamine aimed at alcohol use disorder and treatment-resistant depression using a 505(b)(2) regulatory strategy. Additionally, preclinical development of SVN-015 for methamphetamine and cocaine addiction continues in collaboration with NIDA, reflecting growing commercial interest and M&A activity in CNS and neuro-psychiatry sectors.